Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data

RefinitivMeno di 1 minuto di lettura

Dare Bioscience Inc DARE:

DARÉ BIOSCIENCE ANNOUNCES RETURN OF RIGHTS TO OVAPRENE®; PHASE 3 PROGRAM ONGOING; POSITIVE INTERIM DATA AND GRANT FUNDING POSITION ASSET FOR VALUE-MAXIMIZATION
DARE BIOSCIENCE INC - TERMINATION EFFECTIVE FEBRUARY 2026, DARÉ GAINS FULL CONTROL OF OVAPRENE

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Accedi o crea un account gratuito per leggere queste notizie